Intellia Therapeutics Inc. 2026年度季度报告

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reportingcompany, or an emerging growth company. See definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and Large accelerated filerNon-accelerated filerEmerging growth company If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complyingwith any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.☐ Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes☐No☒ The number of shares outstanding of the registrant’s common stock as of April 30, 2026: 139,722,277 shares. PART I - FINANCIAL INFORMATION Condensed Consolidated Balance Sheets as of March 31, 2026and December 31, 20253 Condensed Consolidated Statements of Cash Flows for theThree Months Ended March 31, 2026 and 20256 Item 3. Quantitative and Qualitative Disclosures About Market Risk PART II - OTHER INFORMATION INTELLIA THERAPEUTICS, INC.Condensed Consolidated Balance Sheets (unaudited)(Amounts in thousands except share and per share data) INTELLIA THERAPEUTICS, INC.Notes to Condensed Consolidated Financial Statements (unaudited) 1. Overview and Basis of Presentation Intellia Therapeutics, Inc. (“Intellia,” or the “Company”) is a leading biopharmaceutical company focused on revolutionizingmedicine leveraging CRISPR gene editing and other core technologies. The Company’s mission is to transform the lives of peoplewith severe diseases by developing and commercializing potentially curative treatments. With deep scientific, technical and clinical For over a decade, Intellia has applied its proprietary technologies and expertise, including CRISPR-based gene editingtechnologies, oligonucleotides, and lipid nanoparticles (“LNPs”), to develop novel, first-in-class product candidates. This includesthe development of lonvoguran ziclumeran (“lonvo-z,” previously referred to as NTLA-2002) for the treatment of hereditaryangioedema (“HAE”) and nexiguran ziclumeran (“nex-z,” previously referred to as NTLA-2001) for the treatment of transthyretin(“ATTR”) amyloidosis. These lead product candidates are the firstin vivogenome editing product candidates to advance into Phase3 clinical development. These systemically administered CRISPR-based candidates are designed to address diseases with highunmet need with a single intravenous (“IV”) infusion that is administered in an outpatient setting. In April 2026, the Company The condensed consolidated financial statements of the Company included herein have been prepared, without audit, pursuant tothe rules and regulations of the Securities and Exchange Commission (“SEC”). Certain information and footnote disclosuresnormally included in annual financial statements prepared in accordance with accounting principles generally accepted in the The unaudited condensed consolidated financial statements include the accounts of Intellia Therapeutics, Inc. and its wholly-owned subsidiary, Intellia Securities Corp. All intercompany balances and transactions have been eliminated in consolidation. The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates, judgments andassumptions that affect the amounts reported in the financial statements and accompanying notes. Significant estimates in thesecondensed consolidated financial statements have been made in connection with the calculation of revenues, research anddevelopment expenses and stock-based compensation expense. The Company bases its estimates on historical experience and In the opinion of management, the information furnished reflects all adjustments, all of which are of a normal and recurring nature,necessary for a fair presentation of the results for the reported interim periods. The Company considers events or transactions thatoccur after the balance sheet date but before the financial statements are issued to provide additional evidence relative to certain Liquidity Since its inception through March 31, 2026, the Company has funded its operations through its initial public offering (“IPO”) andconcurrent private placements, follow-on public offerings, at-the-market offerings and the sale of convertible preferred stock, aswell as through its collaboration agreements. The Company expects that its cash, cash equivalents and marketable securitiesas of 2. Summary of Significant Accounting Policies The Company’s significant accounting policies are described in Note 2, “Summary of Significant Accounting Policies” to theconsolidated financial statements included in its Annual Report for the year ended December 31, 2025. There have been no material Recently Issued Accounting Pronouncements Not Yet Effective In November 2024, the Financial Accounting Standards Board (“FASB”) issu